Clinical Trial Detail

NCT ID NCT02784795
Title A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

cholangiocarcinoma

breast cancer

Advanced Solid Tumor

colon cancer

sarcoma

lymphoma

Therapies

Cisplatin + Gemcitabine + LY3039478

Carboplatin + Gemcitabine + LY3039478

LY3039478 + LY3023414

Abemaciclib + LY3039478

LY3039478 + Taladegib

LY3039478

LY3023414

Age Groups: adult

Additional content available in CKB BOOST